Stock Market News
Cambridge Cognition software making waves in Alzheimer's drug trials
Health software company Cambridge Cognition said on Tuesday that its CANTAB Recruit software is now established in two of the world's largest Alzheimer's phase III drug trials.
The company also reported that an early adopter of the software, which recruits patients for brain health trials without the need for invasive testing or study site visits, has increased its contract value by 24 times in its first year of use, to a total in excess of £1.2m.
The client had initially used the software to assess the recruitment eligibility of 100 patients and will now screen tens of thousands of prospective participants worldwide.
The company has 139 Alzheimer's clinical trials in its development pipeline, up 21% from last year, and is seeking to expand operations for applicability in trials concerning depression and schizophrenia.
Steven Powell, chief executive of Cambridge Cognition, said: "Cambridge Cognition digital health software continues to enable pharmaceutical companies to collect high quality data in ways that improve R&D productivity. CANTAB Recruit is delivering high-value participant screening directly to end-users at scale and is part of the ongoing expansion of CANTAB products from simple endpoint testing to patient finding and patient population definition."
Patient recruitment makes up approximately a third of the costs in clinical drug trials according to Cambridge Cognition, with 80% of programmes suffering delays due to unfulfilled enrolment numbers.
As of 1006 BST, Cambridge Cognitions' shares were up 2.07% at 123.50p.
The company also reported that an early adopter of the software, which recruits patients for brain health trials without the need for invasive testing or study site visits, has increased its contract value by 24 times in its first year of use, to a total in excess of £1.2m.
The client had initially used the software to assess the recruitment eligibility of 100 patients and will now screen tens of thousands of prospective participants worldwide.
The company has 139 Alzheimer's clinical trials in its development pipeline, up 21% from last year, and is seeking to expand operations for applicability in trials concerning depression and schizophrenia.
Steven Powell, chief executive of Cambridge Cognition, said: "Cambridge Cognition digital health software continues to enable pharmaceutical companies to collect high quality data in ways that improve R&D productivity. CANTAB Recruit is delivering high-value participant screening directly to end-users at scale and is part of the ongoing expansion of CANTAB products from simple endpoint testing to patient finding and patient population definition."
Patient recruitment makes up approximately a third of the costs in clinical drug trials according to Cambridge Cognition, with 80% of programmes suffering delays due to unfulfilled enrolment numbers.
As of 1006 BST, Cambridge Cognitions' shares were up 2.07% at 123.50p.
Related share prices |
---|
Cambridge Cognition Holdings (COG) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price